Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AEVI-001 · 2 trials · 1 indication
The ADHD-RS-5 is comprised of 18 frequency items and 12 impairment items. Each frequency item was scored on a scale from 0 = "Never or rarely" to 3 = "Very often". The ADHD-RS-5 total score was calculated as the sum of the 18 frequency item scores. The total score ranges from 0 to 54. Higher scores indicate greater symptom severity. Change from baseline value were calculated as the assessment value minus the baseline value.
| Arm | Type | Description |
|---|---|---|
| AEVI-001 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AEVI-001 | DRUG | Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period. |
| Placebo | DRUG | Oral doses of Placebo will be administered twice daily, during the treatment period. |
Inclusion Criteria: 1. Subject and parent/legally authorized representative (LAR) can speak English fluently and have provided written informed consent, and assent (as applicable) for this study. 2. Subject is 6 to 17 years of age (inclusive) at the time of consent/assent. The date of signature of ...
AEVI-001 is an investigational small molecule being developed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. It is currently in Phase 2 clinical development and has been studied in two completed trials in the United States.
AEVI-001 is being developed by Avalo Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol AVTX. The drug is currently in Phase 2 clinical development for Attention Deficit Hyperactivity Disorder.
AEVI-001 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 2 trials studying the drug in children and adolescents with ADHD have been completed.
AEVI-001 has been studied in two completed Phase 2 clinical trials. NCT03265119 enrolled 69 participants with ADHD and mGluR mutations, and NCT03609619 enrolled 109 participants with ADHD without mGluR mutations. Both trials were conducted in the United States.
AEVI-001 is the investigational name for the drug being developed by Avalo Therapeutics. No alternative names for this drug have been disclosed in the available clinical trial information.